Pharma must rethink manufacturing, says PwC
pharmafile | February 22, 2011 | News story | Manufacturing and Production | pharma manufacturing, pricewaterhousecoopers, pwC
The pharmaceutical industry needs to undertake a radical overhaul in its approach to manufacturing which at present is “inefficient, under-utilised and ill-equipped to cope with new medicines”, according to PricewaterhouseCoopers.
The latest instalment in the consultants’ Pharma 2020 series notes that drugmakers have invested little effort in modernising their manufacturing and distribution processes to date, focusing instead on issues such as R&D productivity and marketing challenges.
“By 2020, many of the medicines the industry makes will be specialist therapies that require totally different manufacturing and distribution techniques from those used to produce small molecules,” says the report.
For example, biologic drugs are generally more susceptible to impurities during production and damage during shipping than chemical drugs and have shorter shelf lives, and this difference becomes even more stark with gene- and tissue-based therapies.
PwC suggests this will mean new medicines may have to be finished near the patient, for example at the pharmacy or point-of care.
A shift in the way medicines are licensed away from a binary approved/rejected model towards ‘live licenses’ – in other words initially limited registrations that can be broadened as experience with a medicine grows – will also have an impact.
Peak sales will be reached over a longer period, so companies will need to build a supply chain that adjusts according to demand and avoids a large upfront investment. Pharmaceutical manufacturers will therefore need to develop adaptable cost structures “that preserve gross margins at each stage of the product lifecycle”, according to PwC.
Health reforms – and a movement towards outcomes-based measures of a drug’s success – will demand that pharmaceutical manufacturers distribute products alongside diagnostics, data and support services. Meanwhile, greater use of electronic health records, e-prescribing and remote monitoring is driving a preference for self-administered medicines delivered in patients’ own homes and communities.
As a result, “pharmaceutical companies will need real-time information to manage wider distribution networks and demand-driven manufacturing and distribution processes”, says the report.
Added to the mix is the opening up of emerging markets which require understanding of patients’ needs and preferences, as well as greater public and regulatory scrutiny of medicine quality that is bringing issues such as traceability to the fore.
Overall, PwC is predicting three major changes to pharmaceutical manufacturing and distribution over the coming decade: the supply chain will become more fragmented, with different models used for different product types and patient segments; distribution and manufacturing will be a differentiator in the marketplace and source of economic value; and information will flow both up and down the supply chain.
“The most successful pharma companies will be those that recognise the underlying value locked in their supply chain and can leverage it as a value and brand differentiator rather than just a cost,” commented Steve Arlington, global advisory pharmaceutical and life sciences leader at PwC.
“Companies that recognise information is the currency of the future, will be those that go the final mile and stand out by 2020.”
The report can be downloaded here.
Phil Taylor
Related Content
Nigerian agency strongly contests that 70% of drugs are fake
Nigeria’s drug regulatory body has fiercely countered claims made by Chief Economist of PwC in …
AZ tops annual R&D spend in UK, Roche is greatest pharma spender worldwide
New findings of a report by PwC have revealed the biggest spenders in R&D worldwide …
Consumers want more from wearables market
The interest in mobile health (mHealth) wearables is gaining traction, but consumers want more affordable …
